ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
MWN-AI** Summary
ImmuCell Corporation (Nasdaq: ICCC), a company focused on animal health products, reported its preliminary, unaudited sales results for the fourth quarter and full year of 2025 on January 8, 2026. For the fourth quarter, total sales reached $7.6 million, reflecting a 1.6% decline compared to the same quarter in 2024. Domestic sales showed a positive trend at $7.0 million, an increase of 8.7%, while international sales plummeted by 52.6% to $0.6 million. The company’s Tri-Shield® product line saw significant growth, achieving sales of $6.0 million—up 41.3%—while revenues from Dual-Force® and other products fell sharply by 53.0%, totaling $1.7 million.
For the full year, total sales amounted to $27.6 million, up 4.3% year-over-year, driven by a 6.5% increase in domestic sales to $24.4 million. However, international sales dropped by 9.6%, totaling $3.3 million. Tri-Shield® sales rose 26.5% to $19.9 million, counteracting a decline in Dual-Force® sales, which fell by 27.4%.
CEO Olivier te Boekhorst expressed optimism about the company's progress in overcoming past supply challenges, noting that the sales performance exceeded expectations. He emphasized the robust demand for Tri-Shield® and the strategic shift towards expanding the First Defense® product line following regulatory hurdles with the Re-Tain® product. ImmuCell plans to pause investment in Re-Tain® and repurpose its resources toward First Defense®.
The company has also reported planned manufacturing improvements aimed at enhancing production efficiency. A conference call is scheduled for January 9, 2026, to discuss these results further and outline ImmuCell's strategic vision moving forward.
MWN-AI** Analysis
ImmuCell Corporation's recent preliminary unaudited sales results for Q4 and the full year of 2025 offer a mixed but cautiously optimistic outlook for investors. Total sales for Q4 reached $7.6 million, reflecting a slight decline of 1.6% compared to the prior year. However, it's notable that domestic sales saw an impressive increase of 8.7%, reaching $7 million, while international sales faced a stark decline of 52.6% due to order timing issues.
The standout performer has been the Tri-Shield® product line, which experienced remarkable growth, contributing $6 million to Q4 sales, up 41.3% year-over-year. This growth indicates a successful shift towards more effective products, diverging from the declining Dual-Force® sales, which slumped by 53.0% in Q4. Investors should pay close attention to this transition as it may signal a strategic pivot towards a more resilient product mix.
Another critical factor affecting ImmuCell's outlook is the delay with the Re-Tain® product line, resulting in an expected write-down of approximately $2.9 million. The management’s decision to focus on expanding the First Defense® product line could enhance long-term profitability. With manufacturing improvements that have already increased output by over 15%, and plans for further enhancements, ImmuCell appears to be optimizing its operations effectively.
However, investors should remain cautious about the company’s international sales challenges and the dependency on strong domestic sales to offset potential declines. The upcoming conferences will provide further clarity.
For current investors, maintaining positions may be wise given the company's proactive measures and robust domestic sales growth. For new investors, positioning in anticipation of product line adjustments and potential recovery in international sales might present an attractive opportunity. Monitoring the company's progress will be vital as it navigates this transitional phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.
Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects to continue providing this prompt, preliminary report on product sales until further notice. The Company will also include a geographic and product line sales breakdown going forward.
Total sales for the three-month period ended December 31, 2025 were $7.6 million, a 1.6% decline compared to the three-month period ended December 31, 2024. For the three-month periods ended December 31:
- Domestic sales were $7.0 million in 2025, an 8.7% increase compared to 2024
- International sales were $0.6 million in 2025, a 52.6% decline compared to 2024
- Tri-Shield® sales were $6.0 million in 2025, a 41.3% increase compared to 2024
- Dual-Force® and other sales were $1.7 million in 2025, a 53.0% decline compared to 2024
Total sales for the twelve-month period ended December 31, 2025, were $27.6 million, a 4.3% increase compared to the twelve-month period ended December 31, 2024. For the twelve-month period ended December 31:
- Domestic sales were $24.4 million in 2025, a 6.5% increase compared to 2024
- International sales were $3.3 million in 2025, a 9.6% decline compared to 2024
- Tri-Shield® sales were $19.9 million in 2025, a 26.5% increase compared to 2024
- Dual-Force® and other sales were $7.7 million in 2025, a 28.2% decline compared to 2024
“Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges,” commented Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell. “This was one of our highest sales quarters ever, without tailwinds from catching up on backorders. Our international business showed a decline, largely due to order timing. We are highly encouraged by the strong growth of our Tri-Shield® product line, which reflects the migration from Dual-Force® products and the acquisition of new dairy and beef customers seeking protection for their calves.”
On December 24, 2025, ImmuCell announced a strategic focus on expanding the success of First Defense® after receiving a United States Food and Drug Administration (FDA) Incomplete Letter for its Re-Tain® product. The FDA issued the Incomplete Letter on December 23, 2025, because the Company’s contract manufacturer did not satisfactorily address previously cited inspectional deficiencies. After considering the financial implications of the resulting delays, the Company decided to pause further investment in Re-Tain® and intends to record an approximately $2.9 million non-cash impairment write-down of certain property, plant and equipment pertaining to Re-Tain® during the fourth quarter of 2025. The Company has identified opportunities to repurpose the majority of the approximately $15.5 million net book value of Re-Tain® assets as of September 30, 2025, for First Defense®.
“The deployment of these assets for First Defense® will expand our liquid processing capacity to meet our needs well into the future, but requires capital for repurposing the building which we are currently assessing,” said Timothy C. Fiori, Chief Financial Officer of ImmuCell. “In the meantime, we have implemented manufacturing improvements that increased output of our lyophilization process by more than 15% year-over-year in 2025 and we plan similar improvements in 2026 with minimal capital investment. This gives us confidence we can meet growth targets for First Defense®.”
During the review of assets and inventory conducted during the three-month period ending December 31, 2025, the Company identified the following additional write-downs, unrelated to Re-Tain®: a $0.1 million non-cash impairment write-down of certain property, plant and equipment, and a $0.6 million write-down primarily of work in process colostrum inventory that was determined to no longer be fit for processing into First Defense®.
“We use a rigorous and disciplined approach to assessing the best-and-highest value use of our resources and have determined that we expect to achieve a higher return from selling this particular colostrum in the market without further processing,” commented Mr. Fiori. “We are confident in our ability to source and process high quality colostrum going forward to meet demand.”
“The strong sales results and excellent progress in expanding manufacturing output further support our decision to focus on First Defense®,” added Mr. te Boekhorst. “Tri-Shield® growth was outstanding, and we have now started a 50% expansion of the sales force by creating two new domestic territories and hiring an international business development executive.” Te Boekhorst continued, “we also plan to complete our ongoing investigational studies for Re-Tain® to attract partners and maximize value. Combined with the successful manufacturing initiatives and the longer-term manufacturing capacity expansion leveraging the former Re-Tain® building and equipment, we are very well positioned for continued growth. In the coming quarters, our focus will be on commercial expansion and creating scalable manufacturing capacity to support that growth.”
| Preliminary, Unaudited Sales Results | ||||
| During the Three-Month Periods Ended December 31, | 2025 | 2024 | ($ Decrease) $ Increase | (% Decrease) % Increase |
| Total Product Sales | $7.6 million | $7.8 million | ($125,000) | (1.6%) |
| Domestic Sales | $7.0 million | $6.4 million | $562,000 | 8.7% |
| International Sales | $620,000 | $1.3 million | ($687,000) | (52.6%) |
| Dual-Force First Defense® Sales | $1.5 million | $3.3 million | ($1.8 million) | (53.7%) |
| Tri-Shield First Defense® Sales | $6.0 million | $4.2 million | $1.7 million | 41.3% |
| During the Twelve-Month Periods Ended December 31, | 2025 | 2024 | $ Increase ($ Decrease) | % Increase (% Decrease) |
| Total Product Sales | $27.6 million | $26.5 million | $1.2 million | 4.3% |
| Domestic Sales | $24.4 million | $22.9 million | $1.5 million | 6.5% |
| International Sales | $3.3 million | $3.6 million | ($347,000) | (9.6%) |
| Dual-Force First Defense® Sales | $6.9 million | $9.6 million | ($2.6 million) | (27.4%) |
| Tri-Shield First Defense® Sales | $19.9 million | $15.8 million | $4.2 million | 26.5% |
| Preliminary, Unaudited Write-Down and Impairment Impact Estimates During the Three-Month Period Ended December 31, 2025 | |
| In millions $ | |
| Re-Tain® property, plant and equipment | $2.9 |
| Other property, plant and equipment | $0.1 |
| Inventory | $0.6 |
| Total | $3.6 |
Conference Calls:
The Company is planning to host a conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss the unaudited top line results and to review the strategic shift to First Defense® and away from Re-Tain® that was first disclosed on December 24, 2025. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until January 16, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #6043808.
The Company is planning to release its full, unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, February 25, 2026 and is planning to host a conference call on Thursday, February 26, 2026 at 9:00 AM ET to discuss these results. Interested parties can access that conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 5, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release and the statements to be made in the related conference call referenced herein contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; estimates of anticipated write-offs relating to equipment, inventory or other assets; projections of future financial or operational performance; future demand for our products; growth in acceptance of our First Defense® product line by dairy and beef producers; future prospects for and investments associated with expanding production of First Defense® product line; future prospects for First Defense® versus Re-Tain®; the timing and outcome of prospective future applications for regulatory approvals and future implications of prior regulatory inspection deficiencies relating to facilities of our contract manufacturer; future regulatory requirements relating to our products; and any other statements that are not historical facts. These statements are intended to provide management's current expectations of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand, uncertainty associated with the timing and volume of customer orders, adverse impacts of possible future supply chain disruptions or shortfalls on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity of First Defense®, and other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts:
Olivier te Boekhorst, President and CEO
Timothy C. Fiori, Chief Financial Officer
ImmuCell Corporation
investor.relations@immucell.com
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LL
iccc@lythampartners.com
FAQ**
What strategic initiatives is ImmuCell Corporation (ICCC) planning to implement in 2026 to address the significant decline in international sales reported for the fourth quarter of 2025?
How does ImmuCell Corporation (ICCC) plan to leverage the repurposed assets from Re-Tain® to enhance First Defense® production and meet growing demand?
Given the impressive growth of Tri-Shield® sales, how does ImmuCell Corporation (ICCC) intend to market and expand this product line in the coming year?
What actions is ImmuCell Corporation (ICCC) taking to ensure a smooth transition away from Re-Tain® while maximizing the potential value of their other product offerings?
**MWN-AI FAQ is based on asking OpenAI questions about ImmuCell Corporation (NASDAQ: ICCC).
NASDAQ: ICCC
ICCC Trading
2.31% G/L:
$6.42 Last:
243 Volume:
$6.42 Open:
